Aviance Capital Management LLC Has $1,892,000 Position in Gilead Sciences Inc. (GILD)
Aviance Capital Management LLC decreased its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 39.2% during the second quarter, Holdings Channel reports. The fund owned 22,684 shares of the biopharmaceutical company’s stock after selling 14,624 shares during the period. Aviance Capital Management LLC’s holdings in Gilead Sciences were worth $1,892,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. First Manhattan Co. boosted its position in shares of Gilead Sciences by 8.3% in the first quarter. First Manhattan Co. now owns 1,671,808 shares of the biopharmaceutical company’s stock valued at $153,572,000 after buying an additional 127,631 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at about $750,000. Vicus Capital boosted its position in shares of Gilead Sciences by 39.3% in the first quarter. Vicus Capital now owns 3,159 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 891 shares in the last quarter. PGGM Investments boosted its position in shares of Gilead Sciences by 13.1% in the first quarter. PGGM Investments now owns 1,086,657 shares of the biopharmaceutical company’s stock valued at $99,820,000 after buying an additional 126,063 shares in the last quarter. Finally, Saddle Road Partners LLC boosted its position in shares of Gilead Sciences by 4.0% in the first quarter. Saddle Road Partners LLC now owns 14,111 shares of the biopharmaceutical company’s stock valued at $1,296,000 after buying an additional 549 shares in the last quarter. Institutional investors and hedge funds own 77.94% of the company’s stock.
Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.27% on Friday, reaching $75.24. The company had a trading volume of 11,149,150 shares. The stock’s 50 day moving average is $78.95 and its 200-day moving average is $85.05. Gilead Sciences Inc. has a 1-year low of $74.92 and a 1-year high of $111.11. The stock has a market capitalization of $99.29 billion, a P/E ratio of 6.60 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. During the same period last year, the business posted $3.15 earnings per share. The firm’s revenue was down 5.7% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences Inc. will post $11.76 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s payout ratio is 16.56%.
A number of analysts recently commented on GILD shares. Barclays PLC reaffirmed an “overweight” rating on shares of Gilead Sciences in a research note on Thursday, July 28th. Royal Bank Of Canada raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Monday, October 3rd. Bank of America Corp. reaffirmed a “neutral” rating and issued a $100.00 price target on shares of Gilead Sciences in a research note on Sunday, September 25th. Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Finally, Leerink Swann set a $112.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, September 22nd. Ten research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $104.71.
In other news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total value of $409,200.00. Following the completion of the transaction, the executive vice president now directly owns 132,964 shares in the company, valued at $10,881,773.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kevin E. Lofton sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $81.97, for a total value of $286,895.00. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.